Table 2.
CXCR4 IC50 values (nM) of the evaluated compounds
| Complex | CXCL12 inhibition (nM) |
Ca2+ flux IC50 CXCR4a (nM) |
|---|---|---|
| [Cu1(OAc)]+ | 28.0 | 186.0 |
| [Zn1(OAc)]+ | 153.5 | 2236.0 |
| [Cu2(OAc)]+ | 16.8 | 298.1 |
| [Zn2(OAc)]+ | 117.7 | 642.5 |
| [Cu3(OAc)]+ | 12.4 | 53.5 |
| [Zn3(OAc)]+ | 195.0 | 2793.8 |
| [Cu4(OAc)]+ | 26.4 | 203.5 |
| [Zn4(OAc)]+ | 21.0 | 40.0 |
| [Cu5(OAc)]+ | 29.8 | 155.8 |
| [Zn5(OAc)]+ | 14.8 | 68.5 |
| [Cu6(OAc)]+ | 44.5 | 231.6 |
| [Zn6(OAc)]+ | 15.0 | 71.0 |
| [Cu8(OAc)]+ | 9.5 | 52.8 |
| [Zn8(OAc)]+ | 0.6 | 1.5 |
| [Cu9(OAc)]+ | 68.8 | 884.1 |
| [Zn9(OAc)]+ | 129.0 | 1163.4 |
| AMD3100 | 11.9 | 87.6 |
CXCR4-positive U87 cell line. IC50 is the concentration of the compound required to inhibit 50% of binding of AF647-labeled CXCL12 (CXCL12 inhibition) the CXCL12 (SDF-1) induced Ca2+ signalling.